RepEconomy.com – by “Sebastian P”

RepEconomy.com and RepEconomy on twitter is the final project of Andrew Gu, Avi Sutton, Kai Chao, Meryln Deng, Sebastian Park, and Shirley Berry.

The goal of this website is to expand on the growing base of information about reputation economies.  This site does not represent all different branches of reputation economies, but it does include different perspectives on how reputation economies are viewed.  We also hope to provide information regarding how reputation economies can be studied (in our game theory and experiment section).

Generally defined, a reputation economy is a group whose “currency” relies on a measure of reputation (diversely defined) within a community or domain.  Reputation measures, while heterogeneous in type, are based on a collection of opinions that other entities hold about the consumable goods.  These opinions come from ratings that are centralized through an algorithm.

On our web site, you will find:

  • Legal implications of real-world reputation economies
  • Our own “car sales” experiment to measure the persistence of reputation over time
  • Examples of real-world reputation economies that span from games to non-profit reputation economies
  • Game theory implications of reputation economies
  • Additional resources for further reading
  • Link to our twitter
  • Link to our presentation from class, which includes a summary of our project initiatives as well as questions that need to be considered.

We are more than happy to answer any questions.  We encourage you to browse through the website.

Copyright: A Day in the Life of Jack – by “Matthew C”

For our final project, Logan, Michael, and I created a short film about a normal college student named Jack who tries to go through a day following copyright law.  He soon realizes how difficult the task is and hilarity (hopefully) ensues.  A scholarly professor type keeps a running tab throughout the day of Jack’s various violations and provides brief explanations of some of the legal issues.  The film should illustrate the massive gap between the letter of the law and the way we live our lives.

We were inspired by articles like the Tehranian reading in which a law professor racks up multi-million dollar damages for seemingly innocuous behavior.  By portraying the logical conclusion of copyright laws, hopefully we’ve helped in the crusade to unmask absurdity.

It’s been a great class and I hope everyone enjoys the video!

Because of issues with the file size, the video had to be uploaded as 8 separate clips.  The following is the link to the first clip of 8. The rest of the clips will automatically play when the first one is complete.

Re:Re:Re:Mix. A project by Brendan Griffiths and Brian Watterson. – by “Brendan G”

Re:Re:Re:Mix is a project about the issues and implications surrounding fair use and copyright law. In 2007 YouTube released Content ID, a system that enables copyright holders to choose in advance whether they want to track, monetize, or remove their content from YouTube entirely. The system uses fingerprinting technology to identify a copyrighted work by comparing audio and video tracks. If either match, the video will be flagged by the system and the copyright holder will be notified. The problem is that Content ID doesn’t consider fair use. And it can’t, because only a human can discern between an infringing work and one that falls under fair use, a doctrine which allows for commentary, news reporting, research, teaching and scholarship, and criticism.

As makers we feel it is important to highlight these problems and inform other artists of their rights. All creative works are referential to some degree, and to prohibit works from entering the zeitgeist of Internet culture is in direct conflict with the original intention of copyright law: to promote the progress of science and useful arts.

re-re-re-mix.com

Fixing the USPTO for America’s businesses – by “Alexander F”

“Believe it or not, in our patent office — now, this is embarrassing — this is an institution responsible for protecting and promoting innovation — our patent office receives more than 80 percent of patent applications electronically, then manually prints them out, scans them, and enters them into an outdated case management system.  This is one of the reasons why the average processing time for a patent is roughly three years.  Imminently solvable; hasn’t been solved yet.”

— President Barack Obama, Forum on Modernizing Government, White House, January 14, 2010

While growing tides of patent reform may be starting to roll in through congress, one of the biggest problems facing the state of patents in America has yet to be addressed: the efficiency of the US Patent and Trademark Office.

As it currently stands, the USPTO is in a state of tremendous disorder. It has a backlog of over 1.2 million patent applications. That is up from a backlog of 770,000 applications in the middle of 2009. This growth has been unprecedented, and sadly the USPTO has been unable to keep pace with this exploding growth.

The efficiency of this government agency has long been a joke of attorneys, due in part to the technological gaps that the President noted above, but also due to a long and continuing tradition of underfunding and understaffing. In mid-June of last year, the USPTO had in its employment 6,285 patent examiners. This staff can only process about 450,000 applications each year, which has made it impossible to handle the growling load of patents sitting in their back yard.

The Patent office itself aims for an 18-month turn around for each of the applications it receives, yet the average processing time currently is estimated to be around 3.5 years, with more complex applications taking even longer. At this rate, the USPTO is only going to sink deeper and deeper into a hole of patent filing backlogs without a ladder to climb out.

So what needs to be done?

Congress seems more worried about the lawsuits surrounding patent filings, acknowledged by the current patent reform bill in the works that notably lacks any solutions to this backlog of gross inefficiency. I feel that while their intentions are good, they have their priorities in the wrong place. Right now, we, as a nation, are trying to pull ourselves out of the financial sinkhole of 2008, and we’re actually getting there, slowly but surely. In the grand plan for economic improvement, much attention has been given to the encouragement of small-business growth and how to best achieve that. The fact is, many small businesses rely heavily upon their ability to secure patent rights for new and exciting ideas before deciding to bring their ideas to the market. While the legal battles around patent violations may have gotten a little ridiculous, and congress should step in, these battles affect the few, while small business growth effects the nation.

Those 1.2 million backlogged patents provide an incredible amount of wealth for the American economy and these small business. It is foreseeable then that by processing these applications more efficiently, the economy as a whole may feel a boost from small business finally securing patents for their exciting innovations. Companies will begin. Jobs will be created. Markets will re-expand.

Thus, I believe that the focus of patent reform right now needs to drive towards improved efficiency and funding. It needs a larger staff and resource system that can support the demand being placed on the system. It needs the tools to make the processing of applications not only digital, but also easy to submit, maintain, and find. It needs to become a component of the bureaucratic American government that is no longer a laughing stock of nation. Congress needs to help the USPTO get back on its feet, evolve into the digital age, and help America recover and thrive once more.

Ready, Set, File! – by “Reynolds H”

On March 4th, United States Senate Judiciary Committee bipartisan leaders released the details of legislation aimed at reforming US patent laws. The new bill makes significant steps toward resolving longstanding conflict in efforts to revamp US law for patent quality and efficiency, and make it more compatible with international laws. The new bill, referred to as the “managers’ amendment“, is being said to provide a much needed boost to innovation. However, the bill must go to the full Senate for a vote, and must be passed in the House of Representatives as well.

The “Managers’ Amendment”  includes nearly all of the improvements to the patent laws that were part of the  Patent Reform Act of 2009, and contains changes to greater balance all users of the patent system. One of the reforms is particularly intriguing, the transition to a first-to-file system. 

Currently, the USPTO runs under a “first-to-invent” system, which as the name suggest, gives rightful ownership of the patent to the first inventor of the innovation.  Under this system there is the potential for the person who invented the innovation first, but failed to file it with the USPTO to be retroactively awarded the patent, thereby possibly leaving the person who filed the patent first to be stripped of it.  This system creates many situations where patents must be disputed between two parties (or more).  The complications of the first-to-invent system are outlined in this example provided by Wikipedia:

Assume Tom conceives of a new mousetrap on January 1, 2006. Tom works diligently from January 1, 2006, to February 1, 2006, to prepare a patent application, and Tom files his patent application on February 1, 2006. Thus, Tom constructively reduced his invention to practice on February 1, 2006. Assume Jerry conceives of the same mousetrap on January 10, 2006, and diligently files a patent application on the new mousetrap on January 20, 2006. Under the first-to-invent system, Tom is entitled to the patent on the mousetrap, because he conceived the mousetrap before Jerry and still worked diligently to reduce it to practice by filing. Actual and constructive reduction to practice should be distinguished. Filing a diligently prepared application constitutes constructive reduction to practice only and can be antedated by evidence of an actual reduction to practice.  If both Tom and Jerry claimed the same invention, the USPTO would institute an interference proceeding between Tom and Jerry to review evidence of conception, reduction to practice and diligence.

As a further extension of the example, assume Tweety conceived of the same mousetrap on December 31, 1990. Tweety never told anyone about the mousetrap and did not work on reducing the mousetrap to practice for many years due to financial reasons. Tweety finally actually reduced the mousetrap to practice on February 15, 2006. Because Tweety did not diligently work to reduce the invention to practice in the period before others’ conception of the same invention, he is not entitled to a patent over Tom or Jerry.

Proponents believe that this transition will serve to rid the confusions of patent ownership leading to interference proceeding, which take away from both USPTO funds as well as degrade the overall efficiency of the US patent system.  Under this first-to-file system, the argument of who initially invented the innovation is moot, thereby allowing USPTO funds and time to be diverted towards further review of the influx of patents. The trainstion also enters the US into the same system that many of the worlds leading nations (UK and Japan), which relieves a major complication to a transition to a more internationalized patent system.  

However, there are plenty of potential drawbacks to this system transition.  Having a firs-to-file system gives incentive for inventors to file patents for innovations which may not be at a quality high enough to deserve a patent.  From a practical standpoint, if emphasis is placed on the speed at which a patent can be filed, the overall quality of the innovation may decrease as a factor of speed. The bill has not been passed yet, so only time will tell if the pros outweigh the cons, hopefully it doesnt turn patent seeking into one big rat race.

Biotech in Thailand: How patents can change a developing nation. – by “Alexander F”

With the ever-increasing controversy and importance of biotech patents here in the United States, the biotech patent world outside of this country gets forgotten sometimes. While biotech is only one small component of the patent application pool each year in America, there are some nations in the world where Biotech patents are surging ahead as one of the principle patent application types. One important example of a nation such as this is Thailand.

Having only the 33rd largest economy in the world, Thailand has been boasting one of the most robust and explosive biotechnology patent growths of the past decade. These types of patents, which are usually extremely difficult and expensive to develop, have been seen by Thailand’s government as a ticket to becoming a world player with serious international clout and economic influence. Despite the meager economic strength when compared to other biotech powerhouses like the US and Japan, Thailand’s government has encouraged the filing of of biotech patents in Thailand with substantial monetary incentives. Taking some lead from Singapore’s great biotech success, the patent growth in Thailand was initially funded by direct government investment in state-of-the art research facilities to attract foreign researchers and businesses. The attractive facilities, tax incentives, and internationally aligned patent policies soon brought in foreign investment and development.

This shift has been reflected in numerous ways on Thailand. The country now sits third behind the US and Japan in terms of estimated biotech patents, and biotech enjoys a much larger ratio of the overall Thai patent application pool than either of the two leading nations. These patents have been in a wide variety of biotech fields but two of the most striking are agricultural biotech patents, and, of course, drug patents. On the agricultural side, the now great success has been with their genetically modified resistant rice. This helped the Thai agricultural economy expand rapidly and has made Thailand the largest exporter of rice in the world. Beyond this, Thailand is one of only five nations in the world with net food exports. This transformation into an agricultural powerhouse has had a ripple effect by also increasing employment rapidly and consuming land in the nation so that today, over 50% of the arable land in Thailand is used for rice production.

The drug advancements have also been extraordinary in the past few years. Major investments from foreign pharmaceutical corporations have made many of the drug patents be held by foreigners, but thankfully the Thai patent laws graciously allow this especially for biotech patents. The success of the drug patent development came last year, when the World Health Organization approved Thailand as a principle producer of the H1N1 Flu Virus vaccine.

The implications of this success may serve as a lesson, or prediction perhaps, for the future of biotech patent law around the world. In Thailand, a developing nation, the government adjusted and augmented patent law to encourage biotech patent growth. This expensive yet high-value growth, in turn, added substantially to Thailand’s economy and world significance. Other nations in Southeast Asia and further abroad may try to follow suit and encourage patent regulation in manners similarly to Thailand. This could be a new key stepping stone for developing nations to not only harness their natural resources, but also their intellectual ones in order to gain world standing and economic expansion.

While it is unclear if there is an overall causation for the economic growth here to be found in the increased number of biotech patent filings, the correlation is striking. The theoretical power of relatively few biotech patents being able to jump start an agricultural economy en masse is undoubt an exciting prospect for the development of biotech patent law and its influence on the developing world.

OncoMice revisited – by “Merlyn D”

I apologize for the lateness of my post, but I wanted to talk to some scientists about their perspectives on OncoMouse.  Mainly, this is to de-mystify some of the questions that we came up with during class.

A disclaimer: The scientist I interviewed is my father, Chuxia Deng.  He did his postdoc with Phil Leder, who designed the modifications for the OncoMouse.   He is the Chief of Mammalian Genetics at NIH, and develops animal models.  I thought he’d be able to inform us on some of our misconceptions about how patents work in the Biotech industry.

Our discussion on Wednesday focused primarily on whether you can own life forms.  The primary disagreement that all of us have had is that patenting life also means ownership over the progeny of these life forms, which is a problematic distinction because the owner did not independently create these progeny.  And, if profits go toward the owner of these patents, that would seem counter-intuitive promoting scientific innovation.

To delve further into the issue of how the scientific field operates with biotech patents, Dr. Deng said that one further distinction we should make is how patents work differently in the industry and in academia.

The OncoMouse, for example, access to both processes and actual animals do not require a license.  “For scientific research only, you can get it for free,” he said.  But the scientist must state that “he will request the tool to only use in his laboratory and for research purposes only, and it will not be transferred to any third party without your permission.”  The barriers to reaching others’ scientific data are far fewer in the academic industry, as well.  He states, “For academic purposes, there are almost no limitations.  In theory, you are prevented from doing it, but they are not going to hunt down academic institutions, since there are too many.”

But if you’re a for-profit company like Dupont (who owns the patent to OncoMouse), a license is necessary for obtaining legal use of the mouse.  He says, “For profit purposes, you must pay taxes.  You have to pay and buy a license, because you are using it for your own benefit.”

The additional dimension to the discussion helps to address the problems of owning transgenic mice who reproduce (addressed in Logan’s earlier post). Indeed, the beauty of having a patent on life forms is that you cannot curb scientific innovation that scientists control themselves; heterozygote oncomice who mate have progency that are 75% oncomice.

To tie this post back to intellectual property, let us return to the question about the ethics of patenting human genes.  If the spirit of patenting is about stimulating scientific innovation and academic progress benefits from these developments, then is the act of patenting justified?  For example, should it be the scientist who profits from the cultivating the cancerous cell line (HeLa) from a patient (Henrietta Lacks’s picture to the right)?   The trade-off is that for-profit industries must apply for a license in order to profit themselves, but the ethical implications go beyond scientific innovation and begs the question: why should a scientist benefit from what a person was born with?  Is it not her contribution to the scientific world that matters?

A world that disallows scientific patenting would mean the downfall of the private industry. This means that all research and innovation must be funded through the government, which would change the landscape of biotech drastically: no more sex-performance enhancing drugs, but no stem cells, either.

Apple’s Battle for Trademarks: Story of iPhone and iPad – by “Kai C”

Trademark is my favorite component of intellectual property law. Both the conceptual framework and practical implementation have been successful. I am satisfied given the knowledge that when I walk into McDonald’s® I will get quality burgers at bargain price through the dollar-menu and when I go into Starbucks® I expect decent overpriced coffee supplemented by world-class service. Both companies have spent enormous amount of time and effort into developing the company image that they have today. Exclusive trademark protect both the businesses and the customers. Businesses can protect and enjoy the image that they have developed and customers can ensure that the products they are purchasing are ensured by a reliable trademark.

Apple is a perfect example of a company that has heavily invested in the image of its brand and all of its trademark products. For example, with the introduction of the Macintosh computer in 1984, the company spent about a million dollars to develop one of the most famous and influential Super Bowl advertisements in history to promote the Macintosh trademark:

It is clear that Apple’s marketing campaigns have created the company as it is today. The value of that bitten Macintosh apple logo is worth more than the market cap of many mid-size firms. I would argue that without such heavy investment into brand image, Apple cannot possibly sell its products at the prices they offer today.

Currently, Apple holds 185 trademarks covering anything from the Apple logo to iPod family, to Chicago font. The full list of trademarks can be found here: http://www.apple.com/legal/trademark/appletmlist.html

The most notable feature of the Apple product line are that Apple ‘i’ products. Adding the ‘i’ before product name is one of the most phenomenal marketing endeavors. Apple currently holds 23 trademarks that follow this feature. The ‘i’ product line serves two important roles. The ‘i’ automatically signifies that the product is guaranteed to be of good value under the Apple name. In addition, Apple tends to add a generic name after the ‘i’, such as iTunes, iPhone, and iPhoto. This method helps consumers to easily identify the product functionality. In comparison, the Zune and the Android do not have names that indicate the products’ function. (The Zune is Microsoft MP3 player and the Android is a Google phone platform).

Now, the problem arises when Apple wants to introduce a new product line under the ‘i’ series when the name has already been taken! In fact, that has happened to two of Apple’s most important products: the iPhone and the iPad.

Steve Jobs announced release of the iPhone in January of 2007, however, the iPhone trademark was already owned by Cisco. Cisco bought a company called Infogear Technology, which had developed a product that combined web access and telephone called the iPhone in 2000. Shortly after Apple’s iPhone was announced, Cisco filed a trademark infringement lawsuit against Apple. Cisco claimed that the trademark lawsuit was a “minor skirmish that was not about money, but about interoperability.” The two companies soon reached an agreement in February that allowed both companies to use the iPhone name in exchange for interoperability between their security, consumer, and business communication products.

Cisco iPhone vs. Apple iPhone

A similar case of trademark overlap occurred to Apple’s recent announcement of the iPad. Despite the controversial name that resembles a product used by majority of the female population, the name was already registered by Fujitsu in 2003. Fujitsu’s iPad is a handheld scanner for retailers that has Wi-Fi, Bluetooth, and VoIP support. In this case, Fujitsu agreed to cede the trademark to Apple after an undisclosed agreement has been reached in March.

Fujitsu iPad vs. Apple iPad

The cases of iPhone and iPad shade light upon an interesting topic of dispute in trademark law. Strict interpretation of trademark law would have prevented Apple from taking on the trademark names iPhone and iPad, which would have damaged the company’s branding effort for past decades. Some would argue that Cisco and Fujitsu were more or less lucky to have owned the trademarks and have benefited handsomely from it. On one hand, the names iPhone and iPad were not very valuable before Apple decided to use those names. Neither Cisco nor Fujitsu made visible attempts to glorify their trademark. Cisco’s lawsuit and bid for interoperability and Fujitsu’s disclosed settlement (which I assume meant some form of benefit offered to Fujitsu) were used as leverage to use an asset that they did not create. Yet, according to trademark law, as long as the products still exist and that the companies pay periodic fees, the trademarks should remain with the first registrar. And it sounds fair that trademarks should be given on a first-come-first-served basis instead of who-can-get-most-famous rubric.

My personal take on these two cases is that Cisco and Fujitsu have all the right to grab whatever Apple is willing to offer to sell their trademarks. They should be compensated for sharing or ceding the trademarks they legally own. And if Apple cannot offer what they expect, then they should have the right to retain their exclusive trademarks. Indeed, they are lucky that they are receiving benefits that they obtained through pure luck. But the rightful owner of a property should have the right to enjoy unexpected value increase. However, I can see convincing arguments from both sides. Legally, the opposing view has no potential to achieve substantial success. It would need to come down to a moral argument for the trademark holders.

Just to end on an interesting note, somewhat related to the topic of Apple trademarks: Perhaps Apple needs to be more aware of market potential of ‘i’ series.

http://stewdio.org/iquit/

The power of a trademark: Why the internet shouldn’t change trademark rules – by “Sebastian P”

The trademark is a powerful tool that although has drawn some ire, continues to be a legitimate way to hold the right to an image or theme through an extended period of time. Before we can even evaluate trademarks however, we must first realize what their original intention was for.

Trademarks have existed as a way to prevent confusion between brands. So that companies have control of what their own image is, trademarks work as a means of preventing others from infringing on their brand.  It makes logical sense that people will want to protect the products of their time and energy. The idea pretty much makes the same amount of sense as it did when the idea first came up… back in the 14th century.

Flash forward nearly 700 years. What do we make of trademarks today? Well, in the modern and digital age, now more than ever, trademarks play an important role in brand management. With the ever growing spread of information and pictures throughout the world, it becomes imperative that companies protect their own image when necessary. Now although not all of what these companies do may seem right, the protection of an image and its brand are a necessity for companies (existing and future ones) to have peace of mind in spreading the brand.

Those who disagree will point out the loss of one of Facebook’s most popular games of all time. The now defunct Scrabulous.

For many, Scrabulous was trademark rearing its ugly head. However, all will admit that scrabulous was a clear ripoff of Scrabble.

Was the style of the block the same? Yup. How about the board positioning? Definitely. The value of the letters? Of course. The color of the double up and triple value squares? All of the same.

Now, don’t get me wrong. When Scrabulous was around, it was an amazingly fun game to play while procrastinating homework. However, few if any will disagree that individuals, not of the Scrabble name (said: Hasbro) profited heavily from a product that was not theirs. With all of the blatant use of what Scrabble was, it was only a matter of time Scrabulous was shut down. Many argue that Scrabulous renewed interest in Scrabble, that it sold more product than had been sold in the many decades since it was first released. Just because a product increases the popularity, doesn’t mean that the unauthorized use of the brand is any better. Although Scrabulous looked, felt, and seemed the same as Scrabble, it wasn’t Scrabble. Hasbro had a problem with that and with good reason. Left to its own vices, Scrabulous could have changed Scrabble in ways Hasbro didn’t want to deal with. A brand is an image that gains value from what it represents. When the item for which it represents fragments, there arises problems.

Don’t believe me? Let’s check out the real world to see a similar phenomenon of trademark violations.

These are Nike Hyperdunks. A shoe head’s dream kicks (Translated: An enthusiastic shoe collector’s valuable pair of shoes). These retail for about $100 USD, but further on in its lifecycle, they will retail for a lot more than one Benjamin. As you can tell in the picture, they look awesome, fit very well, are extremely light for their design, and if Kobe Bryant is to be believed, allow you to jump over a speeding Aston Martin.

Oh, the best part of the shoes you just saw in that picture are that they are fake. 100% authentic made in china ripoffs. These are the real Hyperdunks:

These are the real ones

Can you tell the difference? Not many, if any can. They look the same, feel the same, smell the same, and seem to function the same, but they’re not the same. The weighting is different, the support technology different, and apparently they “feel different” (my brother’s words, not mine). However, to the unsuspecting buyer who’ll probably buy this pair of shoes at a “great” deal for $40 dollars on eBay, they might as well be the same Nike hyperdunks they saw advertised. This shoe represents what Nike trademarked: it’s brand, it’s image, and its product. The nearly identical ripoff represents degradation to all three of those aspects. And so, the discounted shoes not only discount the quality of the merchandise, but then charge the discount to Nike’s reputation tab.

Now, I’m not saying that all copies are as blatantly terrible. Scrabulous functioned well and for all intents and purposes, was Scrabble. Hasbro, however, had every right to get rid of Scrabulous as it could have very well misrepresented its brand (as it did when it was buggy in the beginning). To draw from the loss of Scrabulous that trademarks are a cancer in this society is ridiculous. Trademarks are one of the few things that actually seem to work in the digital age. Why fix a relatively working thing when there are other terribly broken things to fix (*cough* copyright, DMCA, net neutrality, patents…)?

-Sebastian

What Mice Will Do – by “Logan M”

Patents were originally created in a world in which the only patentable objects would be tools (I’m leaving aside processes for the purpose of this post). Tools are, quite simply, machines, without brains or life, and utterly dependent on man for their creation. If the tool was not dependent on man for its creation, it was not patentable, because at that point it becomes a naturally occurring phenomena like a crystal formation.

Not alive.

Modern patent law, however, holds that anything man-made may be patented (within the limits set out by Diamond v. Chakrabarty, including biological organisms. Biological organisms hold are different in a key way from the simple tools that were originally intended to be patented: they are by definition alive.

Alive.

What it means for these biological organisms to be alive is, primarily, that they can reproduce. Because they can reproduce, however, their existence is not indicative of an attempt to create, and therefore not grounds for patent-related lawsuits. Take the OncoMouse, for example. Assume that I’m the patent holder and am trying to regulate this product that I own. I sell two mice to a buyer, and those two mice do what it is that mice do and my buyer ends up having 10 Oncomice. Obviously, someone here has violated my patent by creating unauthorized copies of my “invention”, but who? The buyer did not, through his own actions, create new mice. It seems the only one to blame would be the mouse itself. And what do we do to mice that break the law?

http://www.cartoonstock.com/directory/p/public_execution.asp

This is obviously an insane tactic, however. We do not grant biological organisms other than humans rights and do not punish them accordingly. If, however, the limitations a patent imposes on others to recreate the invention can be violated by the invention itself, the patent ceases to have any relevant meaning. Once any loss of control over the invention on the part of the owner can lead to an ever increasing number of the invention being out in the world, there is no reason to believe that they owner can have rights over the organisms that are created through their own means. It still stands that if someone were to seek out and try to recreate the organism, that may violate patent law, but who would do that if they knew they could simply let nature take its course and bring them a fresh new organism?

Earlier I mentioned that, if a tool were to not be dependent on man for its creation, it should be viewed as an unpatentable naturally occurring phenomenon. However, once the initial biological organism is created, subsequent ones fall into the category of non-man-dependent. From this, it only stands to reason that the newly formed organisms are not subject to patentability, and therefore serve as a way around any patent law that may be attempted to be applied to the situation.

The process to create the Oncomouse notwithstanding, the mouse itself is not a patentable entity. Unless the scientists who created the Oncomouse also made it so that it could not reproduce, the mice will do what mice will do, and the being enters the realm of the natural. And nature has its own inevitable course to follow…

Nature's course.